Article
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
Cancer research - 1 Jan 2010
Wang Liewei, Ellsworth Katarzyna A, Moon Irene, Pelleymounter Linda L, Eckloff Bruce W, Martin Yvette N, Fridley Brooke L, Jenkins Gregory D, Batzler Anthony, Suman Vera J, Ravi Saranya, Dixon J Michael, Miller William R, Wieben Eric D, Buzdar Aman, Weinshilboum Richard M, Ingle James N
Abstract excerpt
Aromatase (CYP19) is a critical enzyme in estrogen biosynthesis and aromatase inhibitors (AI) are employed widely for endocrine therapy in postmenopausal women with breast cancer. We hypothesized that single nucleotide polymorphisms (SNPs) in the CYP19 gene may alter the effectiveness of AI therapy in the neoadjuvant setting. Genomic DNA was obtained for sequencing from 52 women pre-AI and post-AI treatment in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.